pCMV-hARdelta538-614 Citations (1)

Originally described in: A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences.
Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM J Biol Chem. 1994 May 6;269(18):13115-23. PubMed

---

Articles Citing pCMV-hARdelta538-614

Articles

CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Ruschoff JH, Wild P, Moch H, De Bono J, Alimonti A. J Clin Invest. 2020 May 1;130(5):2435-2450. doi: 10.1172/JCI131133. PubMed

If you have published an article using this material, please email us at to have your article added to this page.